


An Indian Business Forum annual publication

VENTURE VOICE

MAGAZINE **JAN 2025** 10TH YEAR EDITION



Uganda Economy 2024

Uganda India Export Data

IBF DATA

Business News



we keep you informed and inspired. Stay updated on the latest trends, success stories, and innovations shaping the future of business within and beyond our UGANDA community.



Growth Towards Nation Building

THE EVOLUTION OF UGANDA'S PHARMACEUTICAL INDUSTRY

Uganda's pharmaceutical industry is gradually evolving, characterized by a growing market and enhanced local production capabilities. As the sector diversifies, there has been an expansion in the types of medications produced, which now include drugs for both human and animal care. However, the industry continues to face significant challenges that hinder its full potential.

Currently, local manufacturers meet only about 10% of the national demand for medicines, while a staggering 90% is imported, primarily from Asian markets. This heavy reliance on imports raises concerns about supply chain vulnerabilities and quality assurance. The pharmaceutical market in Uganda is valued at approximately \$346.30 million, with oncology drugs representing the largest segment, projected to reach a market volume of over \$46.37 million, indicating a slow but steady growth trajectory.

The sector employs about 1,216 individuals and contributes roughly 0.18% to the national GDP. Notable industry players include Kampala Pharmaceutical Industries (KPI), which focuses on essential generic products like antimicrobials and pain relievers, along with other companies such as Quality Chemicals Limited (in partnership with CIPLA), Abacus Parenteral Care, and Rene Industries. Recent positive developments in Uganda's pharmaceutical sector include the establishment of new manufacturing sites and improvements in regulatory frameworks aimed at enhancing production quality. Strategically positioned within the East African region, Uganda has the potential to benefit from regional integration, allowing for diverse market opportunities. As a member of the East African Community (EAC), Uganda is positioned to leverage trade agreements that could enhance market access and reduce dependency on imports through collaborative manufacturing efforts.

The Ugandan government has recently shown increased interest in the pharmaceutical sector, committing over 700 billion UGX to support vaccine manufacturing initiatives. This investment is expected to stimulate growth, supported by infrastructure improvements and incentives for local manufacturers. Health spending underscores this commitment, with around 14% of the national budget allocated to health, providing a foundation for potentially increased support for the pharmaceutical sector.

Furthermore, with rising health needs due to the increasing prevalence of both communicable and non-communicable diseases, there is a growing demand for pharmaceuticals. This presents local companies with the opportunity to fill gaps in essential medicines and health supplies, catering to both local and regional populations. Despite these opportunities, the Ugandan pharmaceutical

sector faces pressing challenges that limit the growth potential of local firms. A notable 75% of pharmaceuticals remain imported, exacerbating the risks of supply chain disruptions and quality control issues. The National Drug Authority (NDA) struggles with inadequate staffing and resources, which hampers effective regulation. This results in delays in inspections and certifications that can compromise drug safety.

High production costs pose another significant barrier, primarily due to the dependence on imported active pharmaceutical ingredients, skilled labor, and elevated capital costs. This financial burden restricts the growth and expansion of local firms. Additionally, the industry suffers from limited investment in research and development, which stifles innovation and competitiveness against imported products. The existing skills gap, paired with a shortage of trained professionals in pharmaceutical manufacturing, complicates operational efficiency and undermines product quality assurance.

For Uganda's pharmaceutical industry to realize its full potential, strategic investments in training, research, and development are essential. Fostering a skilled workforce and enhancing regulatory frameworks will be vital in empowering local manufacturers to effectively meet rising health needs. With ongoing government support and investments, there is hope for a more self-sufficient and resilient pharmaceutical landscape in Uganda, better equipped to serve its population and adapt to the challenges of a globalized market. As the industry navigates this complex environment, the focus remains on balancing growth with sustainability and quality assurance to ensure a brighter future for healthcare in Uganda.

To improve the pharmaceutical sector, it is recommended to strengthen the National Drug Authority's capacity by increasing funding, providing training, and upgrading technology to enhance drug safety standards. Financial incentives, such as low-interest loans or grants, should be offered to support local pharmaceutical production and decrease reliance on imports. Additionally, fostering partnerships between universities and pharmaceutical companies can promote research for medicines that are relevant to local needs. Establishing training programs in industrial pharmacies will also help address the skills gap and ensure that there is a qualified workforce for local manufacturers.

Authored by:

Allan Ssenyondwa –

Director Policy Research and Advocacy UMA

Patrick Kumakech – Policy Analyst UMA